CAPR
Capricor TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The core bull case is that deramiocel is already in active FDA review with a defined August 22, 2026 decision date, HOPE-3 hit primary and key secondary endpoints, the manufacturing site is operational, and cash of about $318 million gives runway through 2027 [#8-K-2026-03-12].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +0.9.
What can break
Cash runway is solid through 2027, but further delays could eventually revive dilution risk.
Momentum
5
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $31.00 · Bull $50.00 · Bear $16.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $53.60
Why
Momentum5 · Δ7d -6.3
Value41 · Δ7d -0.1
Sentiment100 · Δ7d +0.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
5
26% active weight
Current posture
7d trendFlat
Δ7d
-6.3
Δ21d
-51.3
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
100
34% active weight
Current posture
7d trendFlat
Δ7d
+0.9
Δ21d
+31.8
Why this grade
Composite grade C. Momentum 5.2 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.13B
Beta
0.39
Shares Out
57.91M
P/E (TTM) · Derived
-8.6
P/S (TTM)
101.91
P/FCF (TTM) · Derived
-8.55
Rev YoY
-100.0%
EPS YoY
+10.6%
Gross Margin
+84.2%
Op Margin
-778.8%
Net Debt
-$300.18M
Current Ratio
8.42
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology